Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...

But now UK drugs regulator MHRA have approved the new Vertex pill Alyftrek and it's so advanced, trials show patients no longer show up as having CF on vital 'sweat tests'. Now we can reveal this ...

The National Institute for Health and Care Excellence (Nice) is assessing the clinical and cost effectiveness of Alyftrek – a new once-a-day pill to treat the condition. The drug, also known as ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

It markets several CF treatments, including TRIKAFTA/KAFTRIO, ALYFTREK, and ORKAMBI, and is also developing therapies for sickle cell disease, type 1 diabetes, and other conditions. The Boston ...

This progress, along with the recent approval of ALYFTREK in the UK for cystic fibrosis, might have supported the stock's strength despite broader market uncertainties and a 1.8% decline over the ...

On March 7, 2025, the company received approval from the UK’s Medicines and Healthcare products Regulatory Agency for ALYFTREK, a once-daily treatment for cystic fibrosis in patients aged six ...

On March 7, 2025, Vertex Pharmaceuticals announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...